WO2003030722A2 - Magnetic field enhancement of tumor treatment - Google Patents

Magnetic field enhancement of tumor treatment Download PDF

Info

Publication number
WO2003030722A2
WO2003030722A2 PCT/US2002/032444 US0232444W WO03030722A2 WO 2003030722 A2 WO2003030722 A2 WO 2003030722A2 US 0232444 W US0232444 W US 0232444W WO 03030722 A2 WO03030722 A2 WO 03030722A2
Authority
WO
WIPO (PCT)
Prior art keywords
tumor
magnetic field
free radical
created
free radicals
Prior art date
Application number
PCT/US2002/032444
Other languages
French (fr)
Other versions
WO2003030722A3 (en
Inventor
Robert E Sandstrom
Original Assignee
Robert E Sandstrom
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Robert E Sandstrom filed Critical Robert E Sandstrom
Priority to AU2002343495A priority Critical patent/AU2002343495A1/en
Priority to GB0408373A priority patent/GB2396302B/en
Priority to CA2463491A priority patent/CA2463491C/en
Publication of WO2003030722A2 publication Critical patent/WO2003030722A2/en
Publication of WO2003030722A3 publication Critical patent/WO2003030722A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N2/00Magnetotherapy
    • A61N2/002Magnetotherapy in combination with another treatment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/40Applying electric fields by inductive or capacitive coupling ; Applying radio-frequency signals
    • A61N1/403Applying electric fields by inductive or capacitive coupling ; Applying radio-frequency signals for thermotherapy, e.g. hyperthermia
    • A61N1/406Applying electric fields by inductive or capacitive coupling ; Applying radio-frequency signals for thermotherapy, e.g. hyperthermia using implantable thermoseeds or injected particles for localized hyperthermia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/10X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy

Definitions

  • the present invention has to do with the treatment of cancerous tumors.
  • a central problem in cancer treatment is that of preserving healthy tissue while destroying cancerous tissue.
  • radiation therapy generally involves the focusing of radiation on a tumor, at least some healthy tissue generally is located in the irradiated field. This healthy tissue is exposed to and to some degree damaged by the radiation. In chemotherapy healthy tissue is exposed to the chemotherapy agent and may be damaged.
  • a free radical is any chemical species capable of an independent existence that has an unpaired electron in its valence shell.
  • the presence of an unpaired electron in the valence shell causes free radicals to be paramagnetic and exhibit magnetic properties when exposed to a magnetic field.
  • Free radicals may be formed by any of several mechanisms including but not limited to:
  • Ultraviolet induced homolytic fission as may be encountered in laser ablation therapy of tumors; Specific chemical reactions as encountered with pharmacological che.mothe.rapy e.g. bleomycin;
  • Ionizing radiation as the result of external beam irradiation, antibody directed or site selective radio-nucleotide administration or through implantation radiotherapy e.g. prostatic brachyotherapy;
  • Free radicals once generated may recombine.
  • the biologic effects of free radicals in tissue are determined by the net reactive fraction namely the "escape" population that does not recombine rapidly.
  • Factors, which influence pair recombination include the viscosity of the reaction environment, temperature, bystander effects and the quantum state of the free radical.
  • the Eigenfunctions are defined by a set of four quantum numbers: n—the principal quantum number, 1—the orbital quantum number, M ⁇ _the magnetic quantum number and M s _the spin quantum number. Of particular significance to this discussion is the spin quantum number.
  • the spin quantum number for an unpaired orbital electron can assume one of two values either +1/2 or -1/2.
  • the wave distribution function determined by spin quantitization is a vector quantity and subject to influence by a superimposed magnetic field. When two electrons share an orbital space they must have opposite spin polarity. This phenomenon is dictated by the Pauli Exclusion Principal that postulates that no two electrons can occupy the same quantum state.
  • Spin polarity is conventionally referred to as up spin (t) +1/2 or down spin (4) -1/2.
  • Shared valence electrons in the formation of chemical bonds also must have opposite spin polarity. When covalent bonds are severed as in the formation of free radicals spin polarity is preserved .
  • the unpaired electron in the valence orbital of a free radical in a magnetic field will precess in a manner comparable to Larmor precession described for charged particles in classic electrodynamics.
  • Quantum precession leads to spin phase transitions between the singlet state where antiparallel spin vectors apply and triplet states where parallel spin vectors apply.
  • the singlet state is favorable for recombination because antiparallel spin orientation is preserved and a covalent bond can be established.
  • Triplet state configurations are unfavorable for recombination because parallel spin orientation is induced.
  • In a magnetic field there are three triplet state configurations, which are vector quantities that due to precession in the magnetic field are no longer energy equivalent and are said to be nondegenerate .
  • the strength of the applied magnetic field which maximizes the spin phase mixing effect, is dependent on the quantum state of the free radical or the system of free radicals. In general optimum phase mixing is achieved at relatively low magnetic field strengths (0.1-10.0 mTesla) within the hyperfine coupling energy levels of the radical pair.
  • the singlet state (Si) characterized by antiparallel spin vectors will prevail in the absence of a magnetic field when homolytic fission of a covalent bond occurs to form a free radical pair.
  • the triplet states, T-i, To and T +1 are equally probable energy states and are distinct and nondegenerate .
  • the theoretic distribution between singlet and triplet states will be 25% singlet and 75% triplet. Such a distribution will theoretically increase the effective concentration of escape radicals by 75%. In experimental situations the yield is limited by non-quantum factors including viscosity effects, temperature, diffusion and bystander effects. However, increases in escape radical reactivity of 20-40% are documented in experimental systems where free radical escape reactions are measured.
  • the present invention is a method of treating a tumor in which an elevated concentration of free radicals is created in the tumor by one of several methods described.
  • a magnetic field is created that traverses the tumor and that inhibits the recombination of the free radicals in the tumor enhancing escape radical reactivity, which results in enhanced tumoricidal effect.
  • FIG. 1 is an illustration of a tumor being treated by radiation therapy augmented by a magnetic field.
  • FIG. 2 is an illustration of a tumor being treated by strips of implanted radioactive material interspersed with strips of implanted magnetic material.
  • FIG. 3 is an illustration of a tumor into which a magnet has been introduced by a laparoscope.
  • FIG. 4 is an illustration of a tumor that is being treated by a combination, of radioactive beads and magnetic beads .
  • a patient's body 10 is subjected to radiation 12 that travels through the body 10 in a first direction.
  • a magnet 18 is oriented so as to create a magnetic field 20 in the vicinity of a tumor 22 of one miHi Tesla (mT) .
  • the magnet 18 is aligned so that the area of intersection of the radiation and the magnetic field conforms to the outline of the tumor.
  • magnets 18 are electromagnets, as they may be controlled to vary the intensity of the magnetic field over time. In one preferred embodiment, however, static magnets are used as they can be more easily shaped to reflect the cross section of the tumor.
  • the magnetic field may also be induced by magnetite, sprayed or painted magnetic films or implants or any other method of creating a magnetic field.
  • magnetic shielding may be introduced to block ambient magnetic field effects .
  • the radiation 12 used may be gamma ray, x-ray or photon radiation.
  • the term radiation also encompasses sound waves as in ultrasound-induced acoustic cavitation, and radiation 12 may take this form.
  • a tumor 22 may be treated by placing radioactive strips 30 about it. Additionally, magnetic strips 32 are placed to create a magnetic field in the tumor 22.
  • a laparoscope 40 is used to introduce a magnet 42 directly into the tumor.
  • the tumor is then additionally treated with an injection of chemotherapy agents, which could also be from the laparoscope 40 or with radiation as in FIG-. 1.
  • Laparoscope 40 may also include a light source, for performing photon source radiation.
  • laparoscope 40 injects a chemical agent that is activated by light waves to yield free radicals and also includes a light source for activating the chemical agent.
  • FIG. 4 shows a tumor that is being treated by a set of radioactive beads 50 and a set of magnetic beads 52, adapted to create a magnetic field.
  • the magnetic field created is preferably between about 0.1 mTesla and 10 mTesla (10 - 1,000 gauss).
  • the substance that is injected forms free radical pairs that are particularly likely to cause apoptosis (cell death) .
  • the substance that is injected forms free radical pairs that are particularly sensitive to a magnetic field.
  • the free radical pairs produced may be easily induced into the triplet state by way of the application of a low intensity magnetic field.
  • analysis indicates that a magnetic field on the order of 0.1 to 1.0 milliTesla will cause a 30-40% increase in tumor lethality.
  • the equivalent tumoricidal effect is achieved at significantly lower overall radiation levels.
  • higher tumoricidal effect is achieved at equivalent radiation levels .
  • the magnetic effect is a vector quantity
  • the magnetic field in one preferred embodiment, is contoured to fit the topography of an irradiated tumor allowing more focused radiation effect and sparing normal tissues. This topologic modeling complements and improves prior art radiation treatment field design by introducing an independent vector specific variable.
  • At least one preferred embodiment makes use of oscillating or alternating magnetic fields to influence radical reactivity.
  • the frequency of the oscillating or alternating field will be dependent on the short radical recombination time window.
  • Subtle combinatorial magnetic effects which combine static and modulated magnetic field effects, may offer advantages in specific situations.
  • At least one preferred embodiment makes use of modifications of the ambient magnetic field environment to optimize the magnetic effect described.
  • shielding is used to prevent ambient electromagnetic interference.
  • low carbon steel shields are used for this purpose.
  • mumetal shielding is employed. Radical pair recombination as mentioned will be influenced by the biologic reaction environment and modifications to viscosity, temperature and structural properties including cell membranes and organelles may be exploitable parameters to further enhance the tumoricidal benefit described here.
  • the magnetic field and the substances injected are specifically adapted to destroy specific cell constituents that are targeted by known targeting mechanisms, e.g. antigen-antibody targeting.
  • targeting mechanisms e.g. antigen-antibody targeting.
  • the present invention finds application in the fields of health care and medical equipment.

Abstract

A method of treating a tumor, comprising creating an elevated concentration of free radicals in said tumor (22) and creating a magnetic field (20) that traverses said tumor (22) and that inhibits the recombination of said free radicals in said tumor. A magnetic field of 0.1 mTesla to 10 mTesla is generally used for this purpose.

Description

MAGNETIC FIELD ENHANCEMENT OF TUMOR TREATMENT
TECHNICAL FIELD
The present invention has to do with the treatment of cancerous tumors.
BACKGROUND ART
A central problem in cancer treatment is that of preserving healthy tissue while destroying cancerous tissue. Although radiation therapy generally involves the focusing of radiation on a tumor, at least some healthy tissue generally is located in the irradiated field. This healthy tissue is exposed to and to some degree damaged by the radiation. In chemotherapy healthy tissue is exposed to the chemotherapy agent and may be damaged.
Moreover, research has shown that much of the effect of radiation therapy and a substantial component of some approaches to chemotherapy are mediated by free radical effects in tumor tissue. The mechanisms whereby free radicals produce tumor cell death include direct enzymatic effects, DNA damage and induction of apoptotic pathways.
Our understanding of the physics and chemistry of free radicals and paired radicals has gradually increased over the past ten years. A free radical is any chemical species capable of an independent existence that has an unpaired electron in its valence shell. The presence of an unpaired electron in the valence shell causes free radicals to be paramagnetic and exhibit magnetic properties when exposed to a magnetic field. Free radicals may be formed by any of several mechanisms including but not limited to:
Ultraviolet induced homolytic fission as may be encountered in laser ablation therapy of tumors; Specific chemical reactions as encountered with pharmacological che.mothe.rapy e.g. bleomycin;
Ionizing radiation as the result of external beam irradiation, antibody directed or site selective radio-nucleotide administration or through implantation radiotherapy e.g. prostatic brachyotherapy;
Thermal induction as in hyperthermic therapy; or
Ultrasound induced acoustic cavitation.
Free radicals once generated may recombine. The biologic effects of free radicals in tissue are determined by the net reactive fraction namely the "escape" population that does not recombine rapidly. Factors, which influence pair recombination, include the viscosity of the reaction environment, temperature, bystander effects and the quantum state of the free radical. The quantum state of the free radical is defined by the applicable Schrodinger equation (HΨ=EΨ) where H is a Hamiltonian operator and Ψ are sets of wave functions (Eigenfunctions) . The Eigenfunctions are defined by a set of four quantum numbers: n—the principal quantum number, 1—the orbital quantum number, Mι_the magnetic quantum number and Ms_the spin quantum number. Of particular significance to this discussion is the spin quantum number.
The spin quantum number for an unpaired orbital electron can assume one of two values either +1/2 or -1/2. The wave distribution function determined by spin quantitization is a vector quantity and subject to influence by a superimposed magnetic field. When two electrons share an orbital space they must have opposite spin polarity. This phenomenon is dictated by the Pauli Exclusion Principal that postulates that no two electrons can occupy the same quantum state. Spin polarity is conventionally referred to as up spin (t) +1/2 or down spin (4) -1/2. Shared valence electrons in the formation of chemical bonds also must have opposite spin polarity. When covalent bonds are severed as in the formation of free radicals spin polarity is preserved .
The unpaired electron in the valence orbital of a free radical in a magnetic field will precess in a manner comparable to Larmor precession described for charged particles in classic electrodynamics. Quantum precession leads to spin phase transitions between the singlet state where antiparallel spin vectors apply and triplet states where parallel spin vectors apply. The singlet state is favorable for recombination because antiparallel spin orientation is preserved and a covalent bond can be established. Triplet state configurations are unfavorable for recombination because parallel spin orientation is induced. In a magnetic field there are three triplet state configurations, which are vector quantities that due to precession in the magnetic field are no longer energy equivalent and are said to be nondegenerate .
The strength of the applied magnetic field, which maximizes the spin phase mixing effect, is dependent on the quantum state of the free radical or the system of free radicals. In general optimum phase mixing is achieved at relatively low magnetic field strengths (0.1-10.0 mTesla) within the hyperfine coupling energy levels of the radical pair.
The singlet state (Si) characterized by antiparallel spin vectors will prevail in the absence of a magnetic field when homolytic fission of a covalent bond occurs to form a free radical pair. In the presence of a magnetic field of appropriate strength, the triplet states, T-i, To and T+1 are equally probable energy states and are distinct and nondegenerate . The theoretic distribution between singlet and triplet states will be 25% singlet and 75% triplet. Such a distribution will theoretically increase the effective concentration of escape radicals by 75%. In experimental situations the yield is limited by non-quantum factors including viscosity effects, temperature, diffusion and bystander effects. However, increases in escape radical reactivity of 20-40% are documented in experimental systems where free radical escape reactions are measured.
DISCLOSURE OF THE INVENTION
The present invention is a method of treating a tumor in which an elevated concentration of free radicals is created in the tumor by one of several methods described. In addition, a magnetic field is created that traverses the tumor and that inhibits the recombination of the free radicals in the tumor enhancing escape radical reactivity, which results in enhanced tumoricidal effect.
The foregoing and other objectives, features and advantages of the invention will be more readily understood upon consideration of the following detailed description of the invention, taken in conjunction with the accompanying drawings .
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 is an illustration of a tumor being treated by radiation therapy augmented by a magnetic field. FIG. 2 is an illustration of a tumor being treated by strips of implanted radioactive material interspersed with strips of implanted magnetic material.
FIG. 3 is an illustration of a tumor into which a magnet has been introduced by a laparoscope. FIG. 4 is an illustration of a tumor that is being treated by a combination, of radioactive beads and magnetic beads .
BEST MODES OF CARRYING OUT THE INVENTION
Referring to FIG. 1, in a first preferred embodiment a patient's body 10 is subjected to radiation 12 that travels through the body 10 in a first direction. A magnet 18 is oriented so as to create a magnetic field 20 in the vicinity of a tumor 22 of one miHi Tesla (mT) . The magnet 18 is aligned so that the area of intersection of the radiation and the magnetic field conforms to the outline of the tumor. Typically in this operation magnets 18 are electromagnets, as they may be controlled to vary the intensity of the magnetic field over time. In one preferred embodiment, however, static magnets are used as they can be more easily shaped to reflect the cross section of the tumor. The magnetic field may also be induced by magnetite, sprayed or painted magnetic films or implants or any other method of creating a magnetic field. In addition, magnetic shielding may be introduced to block ambient magnetic field effects .
The radiation 12 used may be gamma ray, x-ray or photon radiation. In addition, as used in this application, the term radiation also encompasses sound waves as in ultrasound-induced acoustic cavitation, and radiation 12 may take this form.
Referring to FIG. 2, a tumor 22 may be treated by placing radioactive strips 30 about it. Additionally, magnetic strips 32 are placed to create a magnetic field in the tumor 22.
Referring to FIG. 3, a laparoscope 40 is used to introduce a magnet 42 directly into the tumor. The tumor is then additionally treated with an injection of chemotherapy agents, which could also be from the laparoscope 40 or with radiation as in FIG-. 1. Laparoscope 40 may also include a light source, for performing photon source radiation. In one preferred embodiment, laparoscope 40 injects a chemical agent that is activated by light waves to yield free radicals and also includes a light source for activating the chemical agent.
FIG. 4 shows a tumor that is being treated by a set of radioactive beads 50 and a set of magnetic beads 52, adapted to create a magnetic field.
For any of the above-described techniques, the magnetic field created is preferably between about 0.1 mTesla and 10 mTesla (10 - 1,000 gauss).
In an additional preferred embodiment, substances that form free radical pairs in the presence of radiation
(including among other forms, light radiation) are injected into the tumor or into the vicinity of the tumor. In a variant of this embodiment, the substance that is injected forms free radical pairs that are particularly likely to cause apoptosis (cell death) . In another variant, the substance that is injected forms free radical pairs that are particularly sensitive to a magnetic field. The free radical pairs produced may be easily induced into the triplet state by way of the application of a low intensity magnetic field. In tumor treatment systems where the effectors of tumor cell killing are the escape free radicals, analysis indicates that a magnetic field on the order of 0.1 to 1.0 milliTesla will cause a 30-40% increase in tumor lethality. Accordingly, in one preferred variant of a treatment system using radiation mediated free radical production, the equivalent tumoricidal effect is achieved at significantly lower overall radiation levels. In another variant, higher tumoricidal effect is achieved at equivalent radiation levels . Furthermore, since the magnetic effect is a vector quantity, the magnetic field, in one preferred embodiment, is contoured to fit the topography of an irradiated tumor allowing more focused radiation effect and sparing normal tissues. This topologic modeling complements and improves prior art radiation treatment field design by introducing an independent vector specific variable.
As noted, at least one preferred embodiment makes use of oscillating or alternating magnetic fields to influence radical reactivity. However, the frequency of the oscillating or alternating field will be dependent on the short radical recombination time window. Subtle combinatorial magnetic effects, which combine static and modulated magnetic field effects, may offer advantages in specific situations.
At least one preferred embodiment makes use of modifications of the ambient magnetic field environment to optimize the magnetic effect described. In cases where electronic equipment near to the intended tumor target modifies the electromagnetic environment, shielding is used to prevent ambient electromagnetic interference. In one preferred embodiment, low carbon steel shields are used for this purpose. In another preferred embodiment mumetal shielding is employed. Radical pair recombination as mentioned will be influenced by the biologic reaction environment and modifications to viscosity, temperature and structural properties including cell membranes and organelles may be exploitable parameters to further enhance the tumoricidal benefit described here.
In a further preferred embodiment, the magnetic field and the substances injected are specifically adapted to destroy specific cell constituents that are targeted by known targeting mechanisms, e.g. antigen-antibody targeting. INDUSTRIAL APPLICABILITY
The present invention finds application in the fields of health care and medical equipment.
The terms and expressions which have been employed
5 in the foregoing specification are used as terms of description and not of limitation, and there is no intention, in the use of such terms and expressions, of excluding equivalents of the features shown and described or portions thereof, it being recognized that the scope of the
) invention is defined and limited only by the claims which follow.

Claims

1. A method of treating a tumor, comprising:
(a) creating an elevated concentration of free radicals in said tumor; and (b) creating a magnetic field that traverses said tumor and that inhibits the recombination of said free radicals in said tumor.
2. The method of claim 1, wherein said free radicals are created in said tumor by means of electromagnetic radiation.
3. The method of claim 2, wherein said electromagnetic radiation is in the frequency band from 1010 Hz to 1020 Hz.
4. The method of claim 2, wherein said electromagnetic radiation is m the frequency band from 2*1014 to 1015Hz.
5. The method of claim 2, wherein said electromagnetic radiation is applied to said tumor m conjunction with the introduction of a chemical agent.
6. The method of claim 1, wherein said free radicals are created in said tumor by means of the introduction of a chemical agent.
7. The method of claim 1, wherein said magnetic field is of a magnitude that facilitates the interstate crossing of singlet state free radical pairs to triplet state free radical pairs.
8. The method of claim 1, wherein said magnetic field has a magnitude in. the range of 0.1 Tesla to 10 milli Tesla through said tumor.
9. The method of claim 1, wherein said magnetic field is of a magnitude that inhibits the interstate crossing of triplet state free radical pairs to singlet state free radical pairs .
10. The method of claim 1, wherein said magnetic field is created by at least one magnet positioned exterior to said tumor.
11. The method of claim 1, wherein said magnetic field is created by magnetic particles that are injected into proximity to said tumor.
12. The method of claim 1, wherein said elevated concentration of free radical pairs is created by sound waves.
13. The method of claim 1, wherein said elevated concentration of free radical pairs is created by acoustic cavitation .
14. The method of claim 1, wherein said free radicals interfere with the operation of enzymes within said tumor cells.
15. The method of claim 1, where free radical magnetic effects are contoured, scaled or designed to conform to tumor volume or shape.
16. The method of claim 1, where free radical reactivity is enhanced by introducing electromagnetic shielding to block ambient electromagnetic interference.
PCT/US2002/032444 2001-10-11 2002-10-09 Magnetic field enhancement of tumor treatment WO2003030722A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2002343495A AU2002343495A1 (en) 2001-10-11 2002-10-09 Magnetic field enhancement of tumor treatment
GB0408373A GB2396302B (en) 2001-10-11 2002-10-09 Magnetic field enhancement of tumor treatment
CA2463491A CA2463491C (en) 2001-10-11 2002-10-09 Magnetic field enhancement of tumor treatment

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US32808501P 2001-10-11 2001-10-11
US60/328,085 2001-10-11
US34927002P 2002-01-18 2002-01-18
US60/349,270 2002-01-18

Publications (2)

Publication Number Publication Date
WO2003030722A2 true WO2003030722A2 (en) 2003-04-17
WO2003030722A3 WO2003030722A3 (en) 2003-07-03

Family

ID=26986208

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/032444 WO2003030722A2 (en) 2001-10-11 2002-10-09 Magnetic field enhancement of tumor treatment

Country Status (4)

Country Link
AU (1) AU2002343495A1 (en)
CA (1) CA2463491C (en)
GB (1) GB2396302B (en)
WO (1) WO2003030722A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7125025B2 (en) 2003-05-20 2006-10-24 Skis Rossignol S.A. Snowboard binding
CN107362445A (en) * 2017-08-30 2017-11-21 东北师范大学 Anticancer targeting medicine points to electrostatic field resultant vector intensifier
US20210077821A1 (en) * 2017-12-19 2021-03-18 Medical Development Technologies S.A. Heatable implant device for tumor treatment

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4665898A (en) * 1984-05-23 1987-05-19 Maxwell Laboratories, Inc. Malignancy treatment
US5156587A (en) * 1983-09-01 1992-10-20 Montone Liber J Method for treating malignant cells
US6261831B1 (en) * 1999-03-26 2001-07-17 The United States Of America As Represented By The Secretary Of The Air Force Ultra-wide band RF-enhanced chemotherapy for cancer treatmeat

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3163724D1 (en) * 1980-04-29 1984-06-28 Electro Biology Inc Apparatus for treating an intact animal organism bearing a neoplastic process and undergoing drug treatment
WO1997004830A1 (en) * 1995-07-28 1997-02-13 Gray James R Use of a polarizing field to modify the efficacy of a bioactive agent

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5156587A (en) * 1983-09-01 1992-10-20 Montone Liber J Method for treating malignant cells
US4665898A (en) * 1984-05-23 1987-05-19 Maxwell Laboratories, Inc. Malignancy treatment
US6261831B1 (en) * 1999-03-26 2001-07-17 The United States Of America As Represented By The Secretary Of The Air Force Ultra-wide band RF-enhanced chemotherapy for cancer treatmeat

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7125025B2 (en) 2003-05-20 2006-10-24 Skis Rossignol S.A. Snowboard binding
CN107362445A (en) * 2017-08-30 2017-11-21 东北师范大学 Anticancer targeting medicine points to electrostatic field resultant vector intensifier
US20210077821A1 (en) * 2017-12-19 2021-03-18 Medical Development Technologies S.A. Heatable implant device for tumor treatment
US11691023B2 (en) * 2017-12-19 2023-07-04 Medical Development Technologies S.A. Heatable implant device for tumor treatment

Also Published As

Publication number Publication date
CA2463491C (en) 2011-07-26
WO2003030722A3 (en) 2003-07-03
GB0408373D0 (en) 2004-05-19
CA2463491A1 (en) 2003-04-17
GB2396302A (en) 2004-06-23
AU2002343495A1 (en) 2003-04-22
GB2396302B (en) 2006-05-31

Similar Documents

Publication Publication Date Title
US6926659B1 (en) Magnetic field enhancement of tumor treatment
US9757582B2 (en) Tumor treatment with free radical lifetimes enhanced by persistant low strength magnetic field
Chandrasekharan et al. Using magnetic particle imaging systems to localize and guide magnetic hyperthermia treatment: tracers, hardware, and future medical applications
CA2383465C (en) Device for therapeutic purposes on human tissue, for influencing injected magnetic particles with an alternating electro-magnetic gradient field
US8463397B2 (en) Hyperthermia devices and their uses with nanoparticles
US8427148B2 (en) System for combining magnetic resonance imaging with particle-based radiation systems for image guided radiation therapy
US8684901B1 (en) Electromagnetic radiation treatment for cancer and pathological genetic regulations
US20050090732A1 (en) Therapy via targeted delivery of nanoscale particles
US20080213382A1 (en) Thermotherapy susceptors and methods of using same
US9789328B2 (en) Tumor treatment with free radical lifetimes enhanced by persistent low strength magnetic field
CA2463491C (en) Magnetic field enhancement of tumor treatment
Saliev et al. Bio-effects of non-ionizing electromagnetic fields in context of cancer therapy
US9999779B2 (en) Cell, tissue and organ protection using a magnetic field
Nijhawan et al. Hyperthermia treatments
Sebastian et al. Design and control of field-free region using two permanent magnets for selective magnetic hyperthermia
US10888243B2 (en) Non-invasive method for focal deep-brain stimulation equipment and methodologies
CA1332440C (en) Method and apparatus for treating malignant cells
Orel et al. Magnetic nanotherapeutics of Guerin carcinoma
Abbood Radiation Therapy Use Perhaps for Viruses Treatment
JP7269597B2 (en) Tumor treatment device
WO2017132248A1 (en) Method for increasing and sustaining free radical levels in tissue of interest
KR20220126099A (en) A metal nano-complex for treating cancer to provide radio-sensitization and magnetic hyperthermia effects
US20100286469A1 (en) Device for attenuating cellular metabolism
Tamanoi New radiation therapy for cancer using monochromatic X-rays and nanoparticles
Kalantaryan et al. Electromagnetic nature of cancer origin and millimeter therapy

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ PL PT RO RU SE SG SI SK SL TJ TM TR TT TZ UA US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

ENP Entry into the national phase in:

Ref document number: 0408373

Country of ref document: GB

Kind code of ref document: A

Free format text: PCT FILING DATE = 20021009

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2463491

Country of ref document: CA

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP